The frontline management of chronic lymphocytic leukemia (CLL) has never offered more promise or demanded greater clinical precision. Biomarker-guided treatment selection and an expanding arsenal of targeted therapies are redefining standards of care. However, clinicians continue…
Relapsed/refractory multiple myeloma (RRMM) remains clinically heterogeneous and increasingly difficult to control across successive lines of therapy, particularly among patients with high-risk disease, extramedullary involvement, or cumulative immune compromise. B-cell maturation antigen (BCMA)-targeted bispecific antibodies have…
Neurofibromatosis type 1 (NF1) is a rare, lifelong genetic condition that can predispose individuals to tumor development. Among these are NF1-associated plexiform neurofibromas (PNs), infiltrative tumors that can be difficult to treat surgically, cause significant pain,…
Neurofibromatosis type 1 (NF1) is a rare, lifelong genetic condition that can predispose individuals to tumor development. Among these are NF1-associated plexiform neurofibromas (PNs), infiltrative tumors that can be difficult to treat surgically, cause significant pain,…
Discover how the latest breakthroughs in folate receptor alpha (FRα)-targeted antibody-drug conjugates (ADCs) are redefining what’s possible with biomarker-driven therapy! From landmark clinical findings to promising next-generation ADCs, new treatment opportunities are expanding care across the…
Muscle-invasive bladder cancer (MIBC) remains one of the most aggressive urologic cancers, with poor long-term outcomes driven by limited systemic therapy options and frequent micrometastatic disease at diagnosis. Immune checkpoint inhibitors (ICIs) are transforming the treatment…
Despite significant advances in the management of advanced or recurrent endometrial cancer (EC)—including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies—delivering timely, guideline-compliant care remains complex. Rapidly evolving clinical evidence, the growing role…
Antibody-drug conjugates (ADCs) are redefining precision oncology by delivering potent therapies directly to tumor cells through highly specific molecular targeting. This innovative approach is rapidly becoming a cornerstone of cancer care, particularly in metastatic non-small cell…
Metastatic non-small cell lung cancer (mNSCLC) remains a leading cause of cancer mortality despite advances with targeted therapy and immune checkpoint inhibitors (ICIs). While PD-1/PD-L1 blockade has improved outcomes, most patients ultimately progress, and durable responses…
Driven by new insights into tumor biology and immune response, the therapeutic landscape for advanced renal cell carcinoma (RCC) continues to rapidly expand. As immunotherapy and VEGF-targeted combinations become central to RCC management, oncology teams must…